Non-coding RNAs as key players in neurodegeneration and brain tumors: Insights into therapeutic strategies
نویسندگان
1 Faculty of Pharmacy, Middle East University, Amman, 11831, Jordan
2 Department of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq
3 Marwadi University Research Center, Department of Microbiology, Faculty of Science, Marwadi University, Rajkot-360003, Gujarat, India
4 Department of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India
5 College of Nursing, National University of Science and Technology, Dhi Qar, Iraq
6 Pharmacy college, Al-Farahidi University, Iraq
7 Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
8 Ahl al Bayt University, Karbala, Iraq
9 Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India
10 Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India
11 Department of Public Health and Healthcare Management, Rector, Samarkand State Medical University, 18, Amir Temur Street, Samarkand, Uzbekistan
12 Gilgamesh Ahliya University, Baghdad, Iraq
doi
10.22038/ijbms.2025.85350.18446چکیده
Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and other ncRNA types, have emerged as key regulators in neurodegenerative diseases and brain tumors. This review aims to provide insights into the role of ncRNAs in these conditions and their potential as diagnostic and therapeutic targets. We systematically reviewed literature from databases such as PubMed, Scopus, and Web of Science, applying specific inclusion and exclusion criteria to ensure comprehensive coverage of recent advancements. Although ncRNAs are involved in a range of molecular pathways, challenges in clinical translation, including specificity, cost, and validation, persist. This review highlights innovative strategies to overcome these barriers and promote the clinical application of ncRNAs. Moreover, we explore the emerging role of extracellular vesicle-enriched ncRNAs as cell-free therapeutic options for neurodegenerative diseases. The findings presented here emphasize the need for robust validation and the development of specific ncRNA-based treatments.
